American College of Radiology ACR Appropriateness Criteria®

Post-Treatment Follow-up of Prostate Cancer

Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern for residual or recurrent disease.

D 1	Appropriateness	COE	A L L DDI	D I DDI	D. (24.1			F	inal '	Гаbи	latio	ns		
Procedure	Category	SOE	Adults RRL	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
MRI pelvis without and with IV contrast	Usually appropriate	Strong	O 0 mSv	O 0 mSv [ped]	8	8	0	0	0	1	0	2	3	5	5

References	Study Quality
8 (24434294)	3
10 (24978358)	3
28 (19948393)	4
29 (19921202)	4
30 (18430830)	2
31 (18226441)	1
32 (15064390)	3
33 (23377546)	2
38 (23521479)	2
34 (11418435)	2
35 (20106624)	3
36 (20205350)	2
37 (8501793)	3
39 (23313568)	M
6 (18825386)	3
40 (28216327)	3

Choline PET/CT skull base to mid-thigh	Usually appropriate	Limited	��� 1-10 mSv	7	7	0	1	0	1	2	0	5	7	0
		References		Study Quality		•					•		•	
		8 (24434294)		3										
		50 (19690023)		3										
		46 (23123372)		3										
		45 (23628493)		M										
		44 (23486334)		M										
		54 (22549847)		3										
		48 (22621862)		4										
		49 (23069923)		3										
		51 (19756592)		3										
		52 (20306038)		3										
		53 (17891394)		3 3										
		57 (25319322)												
		47 (30205893)		3 3										
		56 (29425221)												
		55 (30521498)		3										
Fluciclovine PET/CT skull base to mid-thigh	Usually appropriate	Strong	���� 10-30 mSv	0-30				0	0	3	2	6	3	2
		References		Study Quality										
		62 (26960562)		3										
		59 (27091135)		2										
		63 (25907118)		M										
		64 (27746282)		3										
		61 (26053708)		2										
		60 (23591953)		3										
		66 (31216198)		3										
		67 (30179618)		3										
		65 (30589673)		3										
		69 (33427655)		1										

		68 (33517323)			1											
Fluciclovine PET/MRI skull base to mid-thigh	Usually appropriate	Strong	��� 1-10 mSv			7	7	0	0	1	0	2	4	5	3	1
		References			Study Q	uality		·								
		70 (16832632)			3											
		71 (12679398))		1											
		72 (16865395))		3											
		73 (16315004))		3											
		74 (17926036))		3											
		78 (17204699))		2											
		84 (27557844))		3											
		76 (27694178))		4											
		77 (27694179))		4											
		75 (29970541)			3											
PSMA PET/CT skull base to mid-thigh	Usually appropriate	Strong	���� 10-30 mSv)		7	7	1	0	0	1	3	1	4	5	1
		References			Study Q	uality										
		84 (27557844)			3											
		83 (30920593))		2											
		86 (31283605))		2											
		85 (31375469))		2											
		87 (28408526))		4											
		82 (-3194111)			4					•						
DCFPyL PET/CT skull base to mid-thigh	Usually appropriate	Moderate	���� 10-30 mSv)		7	7	0	0	0	0	1	1	10	1	1
		References			Study Q	uality										
		90 (31201249)			4											
		91 (33981607)			Goo	od										
		89 (27908968)			3											
		92 (31676732)			3											

May be appropriate	Limited	O 0 mSv	O 0 mSv [ped]	6	6	1	0	0	2	4	4	3	2	0
	References		Study	v Ouality		ı								
	10 (24978358)			3										
May be appropriate	Moderate	��� 1-10 mSv	≎≎≎≎ 3- 10 mSv [ped]	5	5	0	0	0	3	9	3	0	1	0
	References		Study	y Quality		•	•		•	•		•	•	•
	27 (14571410)			4										
	26 (22417806)			2										
May be appropriate	Expert Consensus	O 0 mSv	O 0 mSv [ped]	5	5	0	0	0	4	12	0	0	0	0
May be appropriate	Limited	୭୭୭ 1-10 mSv	≎≎≎≎ 3- 10 mSv [ped]	5	5	0	0	0	1	12	2	1	0	0
	References		Study	y Quality		•								•
	20 (12639656)			3										
	22 (-3098847)			4										
	23 (23707439)			4										
	21 (9751361)			3										
	24 (20483148)			4										
	25 (23903557)			M										
May be appropriate (Disagreement)	Expert Opinion	❤❤❤ 10-30 mSv		5	5	1	1	7	1	1	0	4	1	0
May be appropriate (Disagreement)	Expert Opinion	ତତତ 1-10 mSv		5	5	0	1	1	1	2	0	4	7	0
	References		Study	y Quality		•								•
	58 (28803358)			2										
May be	T ' ' 1	0.0 0	O 0 mSv	5	5	0	0	0	3	11	1	1	0	0
appropriate	Limited	O 0 mSv	[ped]	3	<u> </u>					11	1	1		
	May be appropriate (Disagreement) May be appropriate (Disagreement)	References	References 10 (24978358) May be References 27 (14571410) 26 (22417806) May be Appropriate Limited Paper 1-10 mSv May be Appropriate 20 (12639656) 22 (-3098847) 23 (23707439) 21 (9751361) 24 (20483148) 25 (23903557) May be Appropriate Expert Opinion CDisagreement) Expert Opinion References Expert Opinion References 25 (28803358) References 26 (28803358) References 27 (14571410) 26 (22417806) References 27 (14571410) 26 (22417806) May be Appropriate Expert Opinion Paper 10-30 mSv 10-	References Study	References Study Quality	References Study Quality	References Study Quality Study Quality	References Study Quality Study Quality	References Study Quality Study Quality	References Study Quality Study Quality	References Study Quality 3 3 3 3 4 3 3 4 3 3	References Study Quality Study Quality	References Study Quality Study Quality	References Study Quality Study Quality

			41 (17440730)				2										
MRI pelvis without IV contrast	May approp	be oriate	Strong	O 0 mSv	,	O 0 mSv [ped]	4	4	0	0	6	6	2	0	1	1	0
			References		,	Study	Quality		•							,	
			8 (24434294)				3										
			10 (24978358)				3										
			28 (19948393)				4										
			29 (19921202)				4										
			30 (18430830)				2										
			31 (18226441)				1										
			32 (15064390)				3										
			33 (23377546)				2										
			38 (23521479)				2										
			34 (11418435)				2										
			35 (20106624)				3										
			36 (20205350)				2										
			37 (8501793)				3										
			39 (23313568)				M										
			6 (18825386)				3										
			40 (28216327)				3			1							
CT abdomen and pelvis without IV contrast	Usually approp		Moderate	��� 1-10 mSv	0	���� 3- 10 mSv [ped]	3	3	5	2	3	0	4	2	0	0	0
			References			Study	/ Quality										
			27 (14571410)				4										
			26 (22417806)				2										
CT chest abdomen pelvis with IV contrast	Usually approp		Expert Consensus	���� 10- mSv	30	���� 3- 10 mSv [ped]	3	3	3	3	10	0	0	0	0	0	0
MRI abdomen and pelvis without IV contrast	Usually approp	y not oriate	Expert Consensus	O 0 mSv	,	O 0 mSv [ped]	3	3	1	3	6	2	2	2	0	0	0

FDG-PET/CT skull base to mid- thigh	Usuall approp	Limited	���� 10- mSv	30	���� 3- 10 mSv [ped]	3	3	2	5	6	1	1	0	1	0	0
		References			Study	Quality										
		79 (16000572)				3										
		80 (8638000)				3										
		81 (15950100)				4										
TRUS prostatectomy bed	Usuall approp	Strong	O 0 mSv	′	O 0 mSv [ped]	3	3	4	4	4	0	2	2	0	0	0
		References			Study	Quality										
		19 (16602039)				2										
		42 (8819374)				3										
		43 (16546462)				2										
CT abdomen and pelvis without and with IV contrast	Usuall approp	Moderate	≎≎≎≎ 10- mSv	30	����� 10-30 mSv [ped]	2	2	5	4	5	0	1	0	0	1	0
		References			Study	Quality										
		27 (14571410)				4										
		26 (22417806)				2										
CT chest abdomen pelvis without IV contrast	Usuall approp	Expert Consensus	���� 10- mSv	30	���� 3- 10 mSv [ped]	2	2	7	2	3	1	2	1	0	0	0
Radiography skeletal survey	Usuall approp	Expert Consensus	��� 1-10 mSv	0	��� 0.3- 3 mSv [ped]	2	2	8	5	3	0	0	0	0	0	0
CT chest abdomen pelvis without and with IV contrast	Usuall approp	Expert Consensus	≎≎≎≎ 10- mSv	30	����� 10-30 mSv [ped]	1	1	9	2	3	0	1	0	0	1	0

Variant 2: Prostate cancer follow-up. Clinical concern for residual or recurrent disease after nonsurgical local and pelvic treatments.

	Appropriateness	COF	4 1 14 DDI	D I DDI	D	3.6.11			F	inal	Tabu	latio	ns		
Procedure	Category	SOE	Adults RRL	Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Choline PET/CT skull base to mid-thigh	Usually appropriate	Limited	��� 1-10 mSv		8	8	0	1	0	1	3	0	3	8	0
		References		Study	Quality										
		45 (23628493)			M										
		44 (23486334)			M										
		124 (27597240))		3										
		125 (28126302))		3										
MRI pelvis without and with IV contrast	Usually appropriate	Strong	O 0 mSv	O 0 mSv [ped]	7	7	0	0	0	1	1	1	6	3	4
		References		Study	Quality										
		38 (23521479)			2										
		Strong O 0 msv [ped] / References Study Quality 38 (23521479) 2 39 (23313568) M 107 (21785087) 3 108 (15375223) 2 109 (15972335) 3 110 (20551184) 2 112 (19130116) 3													
		References Study Quality 38 (23521479) 2 39 (23313568) M 107 (21785087) 3 108 (15375223) 2 109 (15972335) 3 110 (20551184) 2 112 (19130116) 3													
		108 (15375223))	2 M 3 2 3 2 3											
		109 (15972335))	2 M 3 2 3 2											
		110 (20551184))	M 3 2 3 2 3 2 3											
		112 (19130116))	3 2 3 2 3											
		113 (15134982))	3 2 3 2											
		114 (19161194))		3										
		111 (17881141))		2										
		115 (17707266))		3										
		118 (27663393))		3										
		116 (27527896))		2										
		117 (29317377))	2 3											
		120 (31361529)			2										
		119 (30730409))		3										
Fluciclovine PET/CT skull base to mid-thigh	Usually appropriate	Strong	���� 10-3 mSv	0	7	7	0	0	0	0	4	2	5	4	1
		References		Study	Quality										

63 (25907118) M			(2 (25007119)													
126 (24991547) 3 127 (29685521) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 129 (30954940) 1 129 (30954940) 1 129 (30954940) 1 129 (30954940) 1 129 (30954940) 1 129 (30954940) 1 129 (30954940) 1 1 1 1 1 1 1 1 1			`													
127 (29685521) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 1 128 (30954940) 7 7 0 0 0 1 5 0 6 3 1 1			,													
128 (30954940) 1						3										
Fluciclovine PET/MRI skull base to mid-thigh						1										
to mid-thigh appropriate Consensus mSv 7 7 0 0 0 1 1 5 0 6 3 1 PSMA PET/CT skull base to mid- thigh Usually appropriate Limited mSv 10-30 mSv 7 7 1 0 0 0 0 3 2 4 5 1 References Study Quality 82 (-3194111) 4 129 (32531840) 3			128 (30954940))		1			I	1			1			
Limited MSV 7 7 1 0 0 0 3 2 4 5 1			Expert Consensus			7	7	0	0	0	1	5	0	6	3	1
Section Sect			Limited	���� 10-30 mSv		7	7	1	0	0	0	3	2	4	5	1
DCFPyL PET/CT skull base to Usually appropriate			References		Study	Quality										
DCFPyL PET/CT skull base to mid-thigh			82 (-3194111)			4										
May be appropriate Limited May be appropriate Limited May be appropriate Limited May be appropriate Limited O 0 mSv [ped] O 0 mSv O			129 (32531840))		3										
Separate Study Quality S			Limited	���� 10-30 mSv)	7	7	0	0	0	1	0	1	10	1	1
TRUS-guided biopsy prostate May be appropriate			References		Study	Quality		•								
TRUS-guided biopsy prostate May be appropriate Limited O 0 mSv [ped] 6 6 0 0 0 1 1 7 4 1 0 References Study Quality 123 (10974448) 1 122 (-3098926) MRI-targeted biopsy prostate May be appropriate New be appropriate Limited O 0 mSv [ped] 6 0 0 0 0 1 1 7 7 4 1 0 References Study Quality 10 0 mSv [ped]			89 (27908968)		-	3										
TRUS-guided biopsy prostate May be appropriate Limited O 0 mSv [ped] References Study Quality 123 (10974448) 1 122 (-3098926) MRI-targeted biopsy prostate May be appropriate Limited O 0 mSv [ped] 6 6 0 0 0 0 1 1 7 7 4 1 0 References Study Quality 120 (-3098926)			92 (31676732)			3										
123 (10974448) 1 122 (-3098926) 4 MRI-targeted biopsy prostate	TRUS-guided biopsy prostate		Limited		6	6	0	0	0	1	1	7	4	1	0	
MRI-targeted biopsy prostate May be Expert O 0 mSy			References		Study	Quality										
MRI-targeted biopsy prostate May be Franct O 0 mSy			123 (10974448))		1										
MRI-targeted biopsy prostate May be Expert O.O. O. O			122 (-3098926)			4										
appropriate Consensus ComSv [ped] 6 6 0 0 1 2 5 6 0 0	MRI-targeted biopsy prostate	May be appropriate	Expert Consensus	O 0 mSv	O 0 mSv [ped]	6	6	0	0	0	1	2	5	6	0	0
CT abdomen and pelvis with IV Contrast May be appropriate Moderate Moder			Moderate		10 mSv	5	5	0	0	0	1	12	1	2	0	0
References Study Quality			References		Study	Quality										
27 (14571410) 4			27 (14571410)			4										
26 (22417806)			26 (22417806)			2										

MRI abdomen and pelvis without and with IV contrast	May approp		Expert Consensus	O 0 mSv	/	O 0 mSv [ped]	5	5	0	0	0	0	11	4	1	0	0
Bone scan whole body	May approp		Limited	��� 1-1 mSv	0	���� 3- 10 mSv [ped]	5	5	0	0	0	0	13	3	0	0	0
			References			Study	Quality										
			3 (23806388)				3										
			20 (12639656)				3										
			5 (-3102557)	· · · · · · · · · · · · · · · · · · ·			4										
			23 (23707439)	5 (-3102557) 23 (23707439)			4										
Fluoride PET/CT skull base to mid-thigh	May approp (Disagre	riate	Expert Opinion	≎≎≎≎ 10- mSv	-30		5	5	0	0	9	1	1	0	3	2	0
Choline PET/MRI skull base to mid-thigh	May approp (Disagre	riate	Expert Opinion	��� 1-1 mSv	0		5	5	0	0	3	1	2	1	3	6	0
MRI pelvis without IV contrast	May approp		Strong	O 0 mSv	/	O 0 mSv [ped]	4	4	0	0	6	5	3	0	1	1	0

References	Study Quality
38 (23521479)	2
39 (23313568)	M
107 (21785087)	3
108 (15375223)	2
109 (15972335)	3
110 (20551184)	2
112 (19130116)	3
113 (15134982)	2
114 (19161194)	3
111 (17881141)	2
115 (17707266)	3
118 (27663393)	3
116 (27527896)	2
117 (29317377)	3

		120 (31361529))		2										
		119 (30730409))		3										
CT abdomen and pelvis without IV contrast	Usually not appropriate	Moderate	��� 1-10 mSv	���� 3- 10 mSv [ped]	3	3	4	2	4	1	3	2	0	0	0
		References		Study	y Quality										
		27 (14571410)			4										
		26 (22417806)			2										
CT abdomen and pelvis without and with IV contrast	Usually not appropriate	Moderate	\$\$\$\$ 10-30 mSv	₩₩₩₩ 10-30 mSv [ped]	3	3	4	3	6	0	1	1	0	1	0
		References		Study	y Quality										
		27 (14571410)			4										
		26 (22417806)			2										
CT chest abdomen pelvis with IV contrast	Usually not appropriate	Expert Consensus	���� 10-30 mSv	���� 3- 10 mSv [ped]	3	3	2	3	10	0	0	0	1	0	0
MRI abdomen and pelvis without IV contrast	Usually not appropriate	Expert Consensus	O 0 mSv	O 0 mSv [ped]	3	3	3	2	4	2	4	1	0	0	0
FDG-PET/CT skull base to mid-thigh	Usually not appropriate	Expert Consensus	���� 10-30 mSv	���� 3- 10 mSv [ped]	3	3	1	6	4	2	2	0	1	0	0
TRUS prostate	Usually not appropriate	Limited	O 0 mSv	O 0 mSv [ped]	3	3	3	4	6	1	0	0	0	0	0
		References		Study	y Quality										
		93 (10664674)			4										
		121 (7690016)			3										
CT chest abdomen pelvis without IV contrast	Usually not appropriate	Expert Consensus	���� 10-30 mSv	���� 3- 10 mSv [ped]	2	2	5	4	2	1	4	0	0	0	0
CT chest abdomen pelvis without and with IV contrast	Usually not appropriate	Expert Consensus	୫୫୫୫ 10-30 mSv	₩₩₩₩ 10-30 mSv [ped]	2	2	6	4	4	1	1	0	0	0	0

	Radiography skeletal survey	Usually not appropriate	Expert Consensus	��� 1-10 mSv	��� 0.3- 3 mSv [ped]	2	2	8	4	4	0	0	0	0	0	0
--	-----------------------------	-------------------------	---------------------	-----------------	----------------------------	---	---	---	---	---	---	---	---	---	---	---

Variant 3: Metastatic prostate cancer treated by systemic therapy (androgen deprivation therapy [ADT], chemotherapy, immunotherapy). Follow-up.

	Appropria	ateness	g 0.7								F	inal '	Tabu	latio	ns		
Procedure	Catego	ory	SOE	Adults RR		Peds RRL	Rating	Median	1	2	3	4	5	6	7	8	9
Bone scan whole body	Usual appropr		Limited	��� 1-10 mSv	0	���� 3- 10 mSv [ped]	8	8	0	0	0	0	0	3	5	5	3
			References			Study Quality											
		134 (26956538)					4										
CT abdomen and pelvis with IV contrast	Usual appropr		Limited	≎≎≎ 1-10 mSv	0	���� 3- 10 mSv [ped]	7	7	0	0	1	1	0	3	4	5	2
			References			Study	Quality										
			27 (14571410)				4										
		135 (28473088)					4										
CT chest abdomen pelvis with IV contrast	Usual appropr		Limited	ଡଡ଼ଡଡ଼ 10-3 mSv	30	���� 3- 10 mSv [ped]	7	7	0	0	0	2	3	3	5	2	1
			References			Study	Quality										
			27 (14571410)		4												
			135 (28473088))			4										
Choline PET/CT skull base to mid-thigh	Usual appropr	lly riate	Strong	��� 1-10 mSv	0		7	7	0	0	0	1	2	5	3	5	0
			References 45 (23628493)			Study	Quality										
						M											
	44 (23486334)			M													
		137 (25504434)					1										
	<u> </u>		136 (26323576))													
			138 (25808631))			3										

		139 (26768648))	2										
Fluciclovine PET/CT skull base to mid-thigh	Usually appropriate	Limited	≎≎≎≎ 10-30 mSv	7	7	0	0	0	0	1	4	7	4	0
		References		Study Quality										
		143 (26278491))	4										
		142 (24943499))	4										
		145 (31343613) 3												
		144 (33237350))	4										
Choline PET/MRI skull base to mid-thigh	Usually appropriate	Expert Consensus	≎≎≎ 1-10 mSv	7	7	0	0	1	1	2	3	4	5	0
Fluciclovine PET/MRI skull base to mid-thigh	Usually appropriate	Strong	��� 1-10 mSv	7	7	0	0	0	0	4	2	5	5	0
		References		Study Quality										
		70 (16832632)		3										
		71 (12679398)		1										
		72 (16865395)		3										
		73 (16315004)		3										
		74 (17926036)		3										
		78 (17204699)		2										
		76 (27694178)		4										
		77 (27694179)		4										
		140 (31127357))	Good										
		146 (33052718))	2										
PSMA PET/CT skull base to mid- thigh	Usually appropriate	Limited	≎≎≎≎ 10-30 mSv	7	7	1	0	0	0	1	3	5	6	0
		References 154 (32481743)		Study Quality										
				3										
	153 (28758969))	3										
DCFPyL PET/CT skull base to mid-thigh	Usually appropriate	Limited	���� 10-30 mSv	7	7	1	0	0	1	4	1	3	6	0
		References		Study Quality		1								

		155 (31451492)				3											
			156 (33452039)			4											
MRI abdomen and pelvis without and with IV contrast	May approp	v be Expert		O 0 mSv	,	O 0 mSv [ped]	6	6	0	0	1	1	3	6	4	1	0
FDG-PET/CT skull base to mid- thigh	May approp		be Limited		30	���� 3- 10 mSv [ped]	6	6	0	0	1	1	5	6	1	1	1
			References			Study											
			79 (16000572)				3										
			80 (8638000)			3											
			149 (10492189)	3													
			148 (27383216))	M												
			147 (27694167))													
			150 (20975102)			3											
			151 (15867215)			3											
		152 (12031380)					3										
MRI abdomen and pelvis without IV contrast	May approp (Disagre	oriate	Expert Opinion	O 0 mSv	,	O 0 mSv [ped]	5	5	0	1	1	5	5	2	1	0	1
Fluoride PET/CT whole body	May approp (Disagre	riate	Expert Opinion	≎≎≎≎ 10- mSv	30	���� 3- 10 mSv [ped]	5	5	0	0	3	2	3	2	2	4	0
			References		Study Quality												
			140 (31127357))													
			141 (30877561))					1		1						
CT abdomen and pelvis without IV contrast	May approp		Limited	��� 1-10 mSv	0	���� 3- 10 mSv [ped]	4	4	1	1	6	1	5	2	0	0	0
		References			Study Quality												
		27 (14571410)			4												
		135 (28473088)			4												
CT chest abdomen pelvis without IV contrast	May approp		Limited	���� 10- mSv	30	���� 3- 10 mSv [ped]	4	4	0	3	5	3	3	2	0	0	0

			References 27 (14571410)			Study	Quality										
							4										
			135 (28473088)				4										
MRI pelvis without and with IV contrast	May approp		Expert Consensus	O 0 mSv		O 0 mSv [ped]	4	4	0	2	3	4	5	2	0	0	0
CT abdomen and pelvis without and with IV contrast	Usually approp		Limited ⊕⊕⊕⊕ 10-30 mSv		30	����� 10-30 mSv [ped]	3	3	3	3	9	0	0	1	0	0	0
			References			Study											
			27 (14571410)														
			135 (28473088)														
CT chest abdomen pelvis without and with IV contrast	Usually approp		Limited	≎≎≎≎ 10- mSv	30	����� 10-30 mSv [ped]	3	3	3	2	10	0	0	1	0	0	0
			References 27 (14571410)			Study	Quality										
			135 (28473088))													
MRI pelvis without IV contrast	Usually approp		Expert Consensus			O 0 mSv [ped]	3	3	2	3	5	1	4	1	0	0	0
TRUS-guided biopsy prostatectomy bed	Usually approp		Expert Consensus	O 0 mSv		O 0 mSv [ped]	3	3	3	4	7	0	2	0	0	0	0
MRI-targeted biopsy prostatectomy bed	Usually approp		Expert Consensus	O 0 mSv		O 0 mSv [ped]	3	3	3	3	6	2	2	0	0	0	0
Radiography skeletal survey	Usually approp		Expert Consensus	ଡେଡେ 1-10 mSv		��� 0.3- 3 mSv [ped]	2	2	5	5	5	1	0	0	0	0	0
TRUS prostatectomy bed	Usually approp		Expert Consensus	O 0 mSv	/	O 0 mSv [ped]	2	2	6	4	5	0	1	0	0	0	0

Appendix Key

A more complete discussion of the items presented below can be found by accessing the supporting documents at the designated hyperlinks.

Appropriateness Category: The panel's recommendation for a procedure based on the assessment of the risks and benefits of performing the procedure for the specified clinical scenario.

SOE: Strength of Evidence. The assessment of the amount and quality of evidence found in the peer reviewed medical literature for an appropriateness recommendation.

- **References:** The citation number and PMID for the reference(s) associated with the recommendation.
- Study Quality: The assessment of the quality of an individual reference based on the number of study quality elements described in the reference.

RRL: Relative Radiation Level. A population based assessment of the amount of radiation a typical patient may be exposed to during the specified procedure.

Rating: The final rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

Median: The median rating (1-9 scale) for the procedure as determined by the panel during rating rounds.

Final tabulations: A histogram showing the number of panel members who rated the procedure as noted in the column heading (ie, 1, 2, 3, etc.).

Additional supporting documents about the AC methodology and processes can be found at www.acr.org/ac.